Publications

  1. Enninga EAL, Moser JC, Weaver AL, Markovic SN, Brewer JD, Leontovich AA, Hieken TJ, Shuster L, Kottschade LA, Olariu A, Mansfield AS, Dronca RS. Survival of cutaneous melanoma based on sex, age, and stage in the United States, 1992-2011. Cancer Med. 2017 Sep 06 Epub 2017 Sept 06
    View PubMed
  2. Leon-Ferre RA, Kottschade LA, Block MS, McWilliams RR, Dronca RS, Creagan ET, Allred JB, Lowe VJ, Markovic SN. Association between the use of surveillance PET/CT and the detection of potentially salvageable occult recurrences among patients with resected high-risk melanoma. Melanoma Res. 2017 Aug; 27: (4)335-341.
    View PubMed
  3. Youland RS, Packard AT, Blanchard MJ, Arnett AL, Wiseman GA, Kottschade LA, Dronca RS, Markovic SN, Olivier KR, Park SS. 18F-FDG PET response and clinical outcomes after stereotactic body radiation therapy for metastatic melanoma. Adv Radiat Oncol. 2017 Apr-Jun; 2: (2)204-210.
    View PubMed
  4. Leontovich AA, Dronca RS, Nevala WK, Thompson MA, Kottschade LA, Ivanov LV, Markovic SN, Melanoma Study Group of the Mayo Clinic Cancer Center. Effect of the lymphocyte-to-monocyte ratio on the clinical outcome of chemotherapy administration in advanced melanoma patients. Melanoma Res. 2017 Feb; 27: (1)32-42.
    View PubMed
  5. Dronca RS, Mansfield AS, Park SS, Dong H. BCL-2-interacting mediator of cell death (Bim) is a novel biomarker for response to anti-PD-1 therapy in patients with advanced melanoma. Immunotherapy. 2016 Dec; 8: (12)1351-1353.
    View PubMed
  6. Daud AI, Wolchok JD, Robert C, Hwu WJ, Weber JS, Ribas A, Hodi FS, Joshua AM, Kefford R, Hersey P, Joseph R, Gangadhar TC, Dronca R, Patnaik A, Zarour H, Roach C, Toland G, Lunceford JK, Li XN, Emancipator K, Dolled-Filhart M, Kang SP, Ebbinghaus S, Hamid O. Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma. J Clin Oncol. 2016 Dec; 34 (34):4102-4109 Epub 2016 Oct 31
    View PubMed
  7. Mansfield AS, Aubry MC, Moser JC, Harrington SM, Dronca RS, Park SS, Dong H. Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer. Ann Oncol. 2016 Oct; 27: (10)1953-8.
    View PubMed
  8. Kottschade LA, McWilliams RR, Markovic SN, Block MS, Villasboas Bisneto J, Pham AQ, Esplin BL, Dronca RS. The use of pembrolizumab for the treatment of metastatic uveal melanoma. Melanoma Res. 2016 Jun; 26: (3)300-3.
    View PubMed
  9. Dronca RS, Liu X, Harrington SM, Chen L, Cao S, Kottschade LA, McWilliams RR, Block MS, Nevala WK, Thompson MA, Mansfield AS, Park SS, Markovic SN, Dong H. T cell Bim levels reflect responses to anti-PD-1 cancer therapy. JCI Insight. 2016 May 05; 1: (6).
    View PubMed
  10. Hodi FS, Hwu WJ, Kefford R, Weber JS, Daud A, Hamid O, Patnaik A, Ribas A, Robert C, Gangadhar TC, Joshua AM, Hersey P, Dronca R, Joseph R, Hille D, Xue D, Li XN, Kang SP, Ebbinghaus S, Perrone A, Wolchok JD. Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. J Clin Oncol. 2016 May 01; 34: (13)1510-7.
    View PubMed
  11. Ribas A, Hamid O, Daud A, Hodi FS, Wolchok JD, Kefford R, Joshua AM, Patnaik A, Hwu WJ, Weber JS, Gangadhar TC, Hersey P, Dronca R, Joseph RW, Zarour H, Chmielowski B, Lawrence DP, Algazi A, Rizvi NA, Hoffner B, Mateus C, Gergich K, Lindia JA, Giannotti M, Li XN, Ebbinghaus S, Kang SP, Robert C. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. JAMA. 2016 Apr 19; 315: (15)1600-9.
    View PubMed
  12. Dronca R. Turning BiKEs into TriKEs to fight cancer Science Translational Medicine. 2016; 8: (328)328ec35.
  13. Moser JC, Pulido JS, Dronca RS, McWilliams RR, Markovic SN, Mansfield AS. The Mayo Clinic experience with the use of kinase inhibitors, ipilimumab, bevacizumab, and local therapies in the treatment of metastatic uveal melanoma. Melanoma Res. 2015 Feb; 25: (1)59-63.
    View PubMed
  14. Dronca RS, Dong H. A gender factor in shaping T-cell immunity to melanoma. Front Oncol. 2015; 5: ()8.
    View PubMed
  15. Dronca R. To beam or not to beam. Sci Transl Med. 2015; 7(310):310ec179.
  16. Kottschade LA, Grotz TE, Dronca RS, Salomao DR, Pulido JS, Wasif N, Jakub JW, Bagaria SP, Kumar R, Kaur JS, Morita SY, Moran SL, Nguyen JT, Nguyen EC, Hand JL, Erickson LA, Brewer JD, Baum CL, Miller RC, Swanson DL, Lowe V, Markovic SN. Rare presentations of primary melanoma and special populations: a systematic review. Am J Clin Oncol. 2014 Dec; 37: (6)635-41.
    View PubMed
  17. Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, Weber JS, Joshua AM, Hwu WJ, Gangadhar TC, Patnaik A, Dronca R, Zarour H, Joseph RW, Boasberg P, Chmielowski B, Mateus C, Postow MA, Gergich K, Elassaiss-Schaap J, Li XN, Iannone R, Ebbinghaus SW, Kang SP, Daud A. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014 Sep 20; 384: (9948)1109-17.
    View PubMed
  18. Dronca RS, Allred JB, Perez DG, Nevala WK, Lieser EA, Thompson M, Maples WJ, Creagan ET, Pockaj BA, Kaur JS, Moore TD, Marchello BT, Markovic SN. Phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma: a North Central Cancer Treatment Group study, N0675. Am J Clin Oncol. 2014 Aug; 37: (4)369-76.
    View PubMed
  19. Hodi FS, Kefford R, Hamid O, Daud A, Wolchok JD, Hwu WJ, Gangadhar TC, Patnaik A, Joshua AM, Hersey P, Weber JS, Dronca RS, Zarour HM, Gergich K, Li XN, Iannone R, Kang SP, Ebbinghaus S, Robert C. Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL). J Clin Oncol. 2014 Jun 20; 32: (18_suppl)LBA9000.
    View PubMed
  20. Thompson RH, Boorjian SA, Kim SP, Cheville JC, Thapa P, Tarrel R, Dronca R, Costello B, Frank I. Eligibility for neoadjuvant/adjuvant cisplatin-based chemotherapy among radical cystectomy patients. BJU Int. 2014 May; 113(5b):E17-21. Epub 2013 Sep 05.
    View PubMed
  21. Shah DJ, Dronca RS. Latest advances in chemotherapeutic, targeted, and immune approaches in the treatment of metastatic melanoma. Mayo Clin Proc. 2014 Apr; 89: (4)504-19.
    View PubMed
  22. Enninga EA, Holtan SG, Creedon DJ, Dronca RS, Nevala WK, Ognjanovic S, Markovic SN. Immunomodulatory effects of sex hormones: requirements for pregnancy and relevance in melanoma. Mayo Clin Proc. 2014 Apr; 89: (4)520-35.
    View PubMed
  23. Lowe GC, Saavedra A, Reed KB, Velazquez AI, Dronca RS, Markovic SN, Lohse CM, Brewer JD. Increasing incidence of melanoma among middle-aged adults: an epidemiologic study in Olmsted County, Minnesota. Mayo Clin Proc. 2014 Jan; 89: (1)52-9.
    View PubMed
  24. Parikh SA, French CA, Costello BA, Marks RS, Dronca RS, Nerby CL, Roden AC, Peddareddigari VG, Hilton J, Shapiro GI, Molina JR. NUT midline carcinoma: an aggressive intrathoracic neoplasm. J Thorac Oncol. 2013 Oct; 8(10):1335-8.
    View PubMed
  25. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, Dronca R, Gangadhar TC, Patnaik A, Zarour H, Joshua AM, Gergich K, Elassaiss-Schaap J, Algazi A, Mateus C, Boasberg P, Tumeh PC, Chmielowski B, Ebbinghaus SW, Li XN, Kang SP, Ribas A. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013 Jul 11; 369(2):134-44. Epub 2013 Jun 02.
    View PubMed
  26. Zhang BY, Thompson RH, Lohse CM, Dronca RS, Cheville JC, Kwon ED, Leibovich BC. Carbonic anhydrase IX (CAIX) is not an independent predictor of outcome in patients with clear cell renal cell carcinoma (ccRCC) after long-term follow-up. BJU Int. 2013 Jun; 111: (7)1046-53.
    View PubMed
  27. McDonnell S, Bevan G, Riska SM, Costello BA, Longenbach S, Dronca RS, Moynihan TJ, Pitot HC, Quevedo F, Cerhan JR. Association of germ-line genetic variation in the NK3 homeobox 1 gene with overall survival in advanced-stage castrate-resistant prostate cancer (CRPC). J Clin Oncol. 2013 Feb 20; 31: (6_suppl)75.
    View PubMed
  28. Zhang B, Malouf J, Young P, Kohli M, Dronca R. Cardiac Metastasis in Renal Cell Carcinoma without Vena Cava or Atrial Involvement: an Unusual Presentation of Metastatic Disease. Rare Tumors. 2013; 5: (3)e29.
    View PubMed
  29. Mansfield AS, Nevala WK, Dronca RS, Leontovich AA, Shuster L, Markovic SN. Normal ageing is associated with an increase in Th2 cells, MCP-1 (CCL1) and RANTES (CCL5), with differences in sCD40L and PDGF-AA between sexes. Clin Exp Immunol. 2012 Nov; 170(2):186-93.
    View PubMed
  30. Dronca RS, Leontovich AA, Nevala WK, Markovic SN. Personalized therapy for metastatic melanoma: could timing be everything? Future Oncol. 2012 Nov; 8: (11)1401-6.
    View PubMed
  31. Rochet NM, Dronca RS, Kottschade LA, Chavan RN, Gorman B, Gilbertson JR, Markovic SN. Melanoma brain metastases and vemurafenib: need for further investigation. Mayo Clin Proc. 2012 Oct; 87: (10)976-81.
    View PubMed
  32. Leontovich AA, Dronca RS, Suman VJ, Ashdown ML, Nevala WK, Thompson MA, Robinson A, Kottschade LA, Kaur JS, McWilliams RR, Ivanov LV, Croghan GA, Markovic SN. Fluctuation of systemic immunity in melanoma and implications for timing of therapy. Front Biosci (Elite Ed). 2012; 4:958-75. Epub 2012 Jan 01.
    View PubMed
  33. Dronca R, Allred JB, Perez DG, Nevala WK, Lieser EA, Thompson M, Maples WJ, Creagan ET, Pockaj BA, Kaur JS, Moore TD, Marchello BT, Markovic SN. Phase II Study of Temzolomide and Everolimus (RAD001) Therapy for Metastatic Melanoma. Am J Clin Oncol. 2012.
    View PubMed
  34. Jevremovic D, Dronca RS, Morice WG, McPhail ED, Kurtin PJ, Zent CS, Hanson CA. CD5+ B-cell lymphoproliferative disorders: Beyond chronic lymphocytic leukemia and mantle cell lymphoma. Leuk Res. 2010 Sep; 34(9):1235-8. Epub 2010 Apr 01.
    View PubMed
  35. Dronca RS, Jevremovic D, Hanson CA, Rabe KG, Shanafelt TD, Morice WG, Call TG, Kay NE, Collins CS, Schwager SM, Slager SL, Zent CS. CD5-positive chronic B-cell lymphoproliferative disorders: diagnosis and prognosis of a heterogeneous disease entity. Cytometry B Clin Cytom. 2010; 78 Suppl 1: ()S35-41.
    View PubMed
  36. Dronca RS, Loprinzi CL, Hartmann LC. Breast cancer risk reduction: SERMs, surgery, and beyond Menopausal Management. 2009 Mar/Apr; 18(2):14-22.
  37. Dronca RS, Steensma D. VTE and mortality associated with recombinant erythropoietin and darbepoetin for treatment of cancer-associated anemia. Nature Clinical Practice Oncology. 2008; 5:504-5.